Another study performed non-targeted metabolomics analysis on serum samples from patients with active MM (presenting CRAB symptoms, whose sera were collected before treatment) and bortezomib-responding MM (decrease in CRAB symptoms and more than 50% reduction in M protein after four treatment cycles, whose sera was collected 21 days after the 4th cycle), and age-matched healthy donors. Here, MYOM2 is linked to Miyoshi myopathy.